136 related articles for article (PubMed ID: 9759997)
21. Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line.
Datta SN; Allman R; Loh C; Mason M; Matthews PN
Br J Cancer; 1997; 76(3):312-7. PubMed ID: 9252197
[TBL] [Abstract][Full Text] [Related]
22. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
[TBL] [Abstract][Full Text] [Related]
23. Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C.
Kobayashi E; Okabe M; Kono M; Arai H; Kasai M; Gomi K; Lee JH; Inaba M; Tsuruo T
Cancer Chemother Pharmacol; 1993; 32(1):20-4. PubMed ID: 8096440
[TBL] [Abstract][Full Text] [Related]
24. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
Kalsi J; Harland SJ; Feneley MR
Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
[TBL] [Abstract][Full Text] [Related]
25. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study.
Brausi M; Campo B; Pizzocaro G; Rigatti P; Parma A; Mazza G; Vicini A; Stephen RL
Urology; 1998 Mar; 51(3):506-9. PubMed ID: 9510365
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.
Singh SV; Xu BH; Gupta V; Emerson EO; Zaren HA; Jani JP
Cancer Lett; 1995 Aug; 95(1-2):49-56. PubMed ID: 7656243
[TBL] [Abstract][Full Text] [Related]
27. Multidrug resistance in a urothelial cancer cell line after 1-hour mitomycin C exposure.
Birare N; Lwaleed BA; Cooper AJ
J Urol; 2009 Nov; 182(5):2472-6. PubMed ID: 19765756
[TBL] [Abstract][Full Text] [Related]
28. The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines.
van der Heijden AG; Jansen CF; Verhaegh G; O'donnell MA; Schalken JA; Witjes JA
Eur Urol; 2004 Nov; 46(5):670-4. PubMed ID: 15474281
[TBL] [Abstract][Full Text] [Related]
29. Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors.
Wajsman Z; Dhafir RA; Pfeffer M; MacDonald S; Block A; Dragone N; Pontes JE
J Urol; 1984 Jul; 132(1):30-3. PubMed ID: 6427484
[TBL] [Abstract][Full Text] [Related]
30. Phase I clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder.
Abbo AH; Jones DR; Masters AR; Stewart JC; Fourez L; Knapp DW
J Vet Intern Med; 2010; 24(5):1124-30. PubMed ID: 20695986
[TBL] [Abstract][Full Text] [Related]
31. [Complications of intravesical mitomycin chemotherapy, apropos of 2 clinical case reports].
Pouya M; Opsomer RJ; Wese FX; Saleh M; Donnay M; Van Cangh PJ
Acta Urol Belg; 1996 Mar; 64(1):47-53. PubMed ID: 8659335
[TBL] [Abstract][Full Text] [Related]
32. Engagement of integrinβ1 induces resistance of bladder cancer cells to mitomycin-C.
Zhang CJ; Shen ZJ; Pan CW; Zhong S; Li T; Zhang MG
Urology; 2012 Mar; 79(3):638-43. PubMed ID: 22386417
[TBL] [Abstract][Full Text] [Related]
33. Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line.
Singh SV; Scalamogna D; Xia H; O'Toole S; Roy D; Emerson EO; Gupta V; Zaren HA
Int J Cancer; 1996 Mar; 65(6):852-7. PubMed ID: 8631603
[TBL] [Abstract][Full Text] [Related]
34. The stability and antitumor activity of recycled (intravesical) mitomycin C.
Hopkins SC; Buice RG; Matheny R; Soloway MS
Cancer; 1984 May; 53(10):2063-8. PubMed ID: 6423261
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of human bladder carcinoma cell chemosensitivity to Mitomycin C through quasi-monochromatic blue light (λ = 453 ± 10 nm).
Hegmann L; Sturm S; Niegisch G; Windolf J; Suschek CV
J Photochem Photobiol B; 2022 Nov; 236():112582. PubMed ID: 36272336
[TBL] [Abstract][Full Text] [Related]
36. Drug resistance restricts the efficacy of short term low dose Mitomycin-C treatment in UMUC-3 bladder cancer cells.
Gul M; Goktas S; Kars MD; Kaynar M
Arch Esp Urol; 2018 Nov; 71(9):783-793. PubMed ID: 30403381
[TBL] [Abstract][Full Text] [Related]
37. Intravesical chemotherapy. Studies on the relationship between pH and cytotoxicity.
Groos E; Walker L; Masters JR
Cancer; 1986 Sep; 58(6):1199-203. PubMed ID: 3091241
[TBL] [Abstract][Full Text] [Related]
38. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Böhle A; Bock PR
Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of the antitumor activity of M-16 and M-18, major metabolites of a new mitomycin C derivative KW-2149, in mice.
Ashizawa T; Okamoto A; Okabe M; Kobayashi S; Arai H; Saito H; Kasai M; Gomi K
Anticancer Drugs; 1995 Dec; 6(6):763-70. PubMed ID: 8845489
[TBL] [Abstract][Full Text] [Related]
40. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Mobley WC; Loening SA; Narayana AS; Culp DA
Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
